Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer: circulating tumor DNA analysis of a randomized phase 3 trial.

Saved in:
Bibliographic Details
Title: Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer: circulating tumor DNA analysis of a randomized phase 3 trial.
Authors: Jongbloed EM; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands., Wortelboer N; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands., de Weerd V; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands., Beaufort CM; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands., Ruigrok-Ritstier K; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands., Van MN; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands., Kraan J; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands., van Zweeden AA; Department of Medical Oncology, Amstelland Hospital, Amstelveen, the Netherlands., van der Padt-Pruijsten A; Department of Internal Medicine, Maasstad Hospital, Rotterdam, the Netherlands., Hamming LC; Department of Medical Oncology, Frisius MC Leeuwarden, Leeuwarden, the Netherlands., Konings IR; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands., Sonke GS; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Oomen-de Hoop E; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands., Martens JWM; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands., Jager A; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands., Wilting SM; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands. s.wilting@erasmusmc.nl.
Source: Nature medicine [Nat Med] 2025 Nov; Vol. 31 (11), pp. 3662-3667. Date of Electronic Publication: 2025 Sep 04.
Publication Type: Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial
Journal Info: Publisher: Nature Publishing Company Country of Publication: United States NLM ID: 9502015 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1546-170X (Electronic) Linking ISSN: 10788956 NLM ISO Abbreviation: Nat Med Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40908356
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer: circulating tumor DNA analysis of a randomized phase 3 trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Jongbloed+EM%22">Jongbloed EM</searchLink>; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Wortelboer+N%22">Wortelboer N</searchLink>; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands.<br /><searchLink fieldCode="AU" term="%22de+Weerd+V%22">de Weerd V</searchLink>; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Beaufort+CM%22">Beaufort CM</searchLink>; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Ruigrok-Ritstier+K%22">Ruigrok-Ritstier K</searchLink>; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Van+MN%22">Van MN</searchLink>; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Kraan+J%22">Kraan J</searchLink>; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands.<br /><searchLink fieldCode="AU" term="%22van+Zweeden+AA%22">van Zweeden AA</searchLink>; Department of Medical Oncology, Amstelland Hospital, Amstelveen, the Netherlands.<br /><searchLink fieldCode="AU" term="%22van+der+Padt-Pruijsten+A%22">van der Padt-Pruijsten A</searchLink>; Department of Internal Medicine, Maasstad Hospital, Rotterdam, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Hamming+LC%22">Hamming LC</searchLink>; Department of Medical Oncology, Frisius MC Leeuwarden, Leeuwarden, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Konings+IR%22">Konings IR</searchLink>; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Sonke+GS%22">Sonke GS</searchLink>; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Oomen-de+Hoop+E%22">Oomen-de Hoop E</searchLink>; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Martens+JWM%22">Martens JWM</searchLink>; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Jager+A%22">Jager A</searchLink>; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Wilting+SM%22">Wilting SM</searchLink>; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands. s.wilting@erasmusmc.nl.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229502015%22">Nature medicine</searchLink> [Nat Med] 2025 Nov; Vol. 31 (11), pp. 3662-3667. <i>Date of Electronic Publication: </i>2025 Sep 04.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Publishing+Company%22">Nature Publishing Company </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9502015 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1546-170X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210788956%22">10788956 </searchLink><i>NLM ISO Abbreviation: </i>Nat Med <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40908356
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s41591-025-03935-w
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 3662
    Titles:
      – TitleFull: Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer: circulating tumor DNA analysis of a randomized phase 3 trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Jongbloed EM
      – PersonEntity:
          Name:
            NameFull: Wortelboer N
      – PersonEntity:
          Name:
            NameFull: de Weerd V
      – PersonEntity:
          Name:
            NameFull: Beaufort CM
      – PersonEntity:
          Name:
            NameFull: Ruigrok-Ritstier K
      – PersonEntity:
          Name:
            NameFull: Van MN
      – PersonEntity:
          Name:
            NameFull: Kraan J
      – PersonEntity:
          Name:
            NameFull: van Zweeden AA
      – PersonEntity:
          Name:
            NameFull: van der Padt-Pruijsten A
      – PersonEntity:
          Name:
            NameFull: Hamming LC
      – PersonEntity:
          Name:
            NameFull: Konings IR
      – PersonEntity:
          Name:
            NameFull: Sonke GS
      – PersonEntity:
          Name:
            NameFull: Oomen-de Hoop E
      – PersonEntity:
          Name:
            NameFull: Martens JWM
      – PersonEntity:
          Name:
            NameFull: Jager A
      – PersonEntity:
          Name:
            NameFull: Wilting SM
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 11
              Text: 2025 Nov
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1546-170X
          Numbering:
            – Type: volume
              Value: 31
            – Type: issue
              Value: 11
          Titles:
            – TitleFull: Nature medicine
              Type: main
ResultId 1